<DOC>
	<DOCNO>NCT03039088</DOCNO>
	<brief_summary>This prospective observational national ( France ) study 2 visit 3 month apart ( baseline 12 week TNF alpha blocker initiation ) . The objective recruitment 500 SpA patient ( diagnosis accord treat rheumatologist ) initiate TNF alpha blocker . The main objective study evaluate impact concomitant fibromyalgia anti-TNF treatment effect axial Spondyloarthritis anti-TNF naïve pre-exposed patient .</brief_summary>
	<brief_title>PREDICT-SpA - French Epidemiological Study Evaluation Impact Fibromyalgia TNF Alpha Treatment Effect Axial Spondyloarthritis Both Anti-TNF naïve - Experienced Patients</brief_title>
	<detailed_description>Background : Diagnosis SpA absence objective sign inflammation structural damage challenging , especially difficult differentiate Fibromyalgia . Furthermore , patient easily classify active refractory NSAIDs , inappropriately receive TNF alpha blocker . Objective : Primary objective : To evaluate impact fibromyalgia TNF alpha treatment effect axial Spondyloarthritis anti-TNF naïve - experienced patient . Methods : Design : Prospective observational national ( France ) study 2 visit 3 month apart ( baseline 12 week TNF alpha blocker initiation ) . Patients : 500 SpA patient ( diagnosis accord treat rheumatologist ) initiate TNF alpha blocker . Data collection : item permit calculation ASAS criterion , FIRST questionnaire ( Fibromyalgia Rapid Screen Test ) , patient disease characteristic , disease activity severity item , domain lead doctor 's decision initiating TNF alpha blocker ( CRP/Imaging/Symptoms ) collect baseline . Effectiveness measure ( e.g . BASDAI patient 's global ) doctor 's decision continue/discontinue TNF alpha blocker collect second visit . Statistical analysis : main objective , evaluation predictive factor TNF alpha response real life , impact Fibromyalgia response ( e.g . logistic regression estimate BASDAI reduction 50 % ) . For secondary objective : evaluation relative attributable risk doctor 's domain lead TNF alpha blocker initiation ( Imaging/CRP/Symptoms ) order explain anti-TNF therapy response ; evaluation concordance exist current recommendation daily practice . Expected result : A positive finding might result change way manage patient ( e.g . carefully check co-existence fibromyalgia confirm spondyloarthritis diagnosis , active disease also initiate specific therapy biologics .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Patients age &gt; 18 year old suffer SpA base opinion treat rheumatologist Patients decision initiate switch antiTNF axial involvement SpA make treat rheumatologist . In case previous exposure antiTNF washout period least 4 week ask . Patients unable understand questionnaire Patients give inform write consent Patients absolute contraindication antiTNF per label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>